



6th July, 2026

Corporate Relationship Department
M/s. BSE Limited
Mumbai 400001

The Manager - Listing
M/s. National Stock Exchange of India Ltd
Bandra (E) Mumbai 400051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub:- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited subject, we would like to inform you that in accordance with the provisions of Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the below mentioned officials of the Company has been designated as follows w.e.f. 6th July, 2026:

1. Mr. Gnanadeva Chalapathy Gudipati has been designated as Senior Vice President - Analytical Research & Development; and
2. Mr. Madhava Rao Karicherla has been designated as Vice President – Formulation Research & Development, Pharma Division, Kothur Unit.

The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 and SEBI Master Circular No.HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 updated on January 30, 2026 are as under:

Sl. No.	PARTICULARS		
1	Name	Mr. Gnanadeva Chalapathy Gudipati	Mr. Madhava Rao Karicherla
2	Reason for Change in Senior Management	Designated as Senior Vice President - Analytical Research & Development	Designated as Vice President – Formulation Research & Development, Pharma Division, Kothur Unit
3	Date of Appointment & Term of Appointment	6 th July, 2026 & Terms of appointment are as per the Company's Policy	6 th July, 2026 & Terms of appointment are as per the Company's Policy
4	Brief profile	Mr. Gnanadeva Chalapathy Gudipati has rich experience in resolving complex technical problems in support of corporate goals and objectives using scientific innovation, project management, learning, leadership & ingenuity. Exposure to corporate operational / technical aspects, technical due-diligence, Internal and External audits, technical write-ups & out-licensing. He has successfully developed Complex injectable portfolio for the organisation by developing complex analytical methods and validating those	Mr. Madhava Rao is an Innovative and Performance-driven Pharmaceutical Professional with 20 plus years of rich and extensive experience in global Generic product development, ANDA Filings, Project Life Cycle Management, Operations Management, Procurement Strategy, Quality Management, Budgeting, Team Management, and People Management across Pharmaceutical Industry. He is also having expertise in Pre-formulation and formulation development of Oral Solid Dosage forms (OSD's) (Immediate



Natco Pharma Limited

Regd. Off : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

		<p>for the regulatory submissions as a part of product characterization through strong reverse engineering skills.</p> <p>He is associated with Natco Pharma Limited since 15th September, 2017. Prior to joining with NATCO Pharma Limited he worked with Mylan Laboratories Limited</p> <p>He has done Executive Programme in Operations Management from Indian Institute of Management, Kozhikode and Master's degree in Chemistry from Institute of Chemical Sciences, Indore, Madhya Pradesh.</p>	<p>release and extended-release tablets, DR capsules), liquid orals and parenteral dosage forms (dry powder injections, lyophilized preparations, liquid injections (aqueous and oily). He is also experienced in designing and implementation of first-to-file patent non-infringing strategies for USA and European markets and exposure to Patents and Patent infringement analysis to design patent non-infringing ANDAs for regulated markets.</p> <p>He is associated with Natco Pharma Limited since 15th November, 2024. Prior to joining with NATCO Pharma Limited Mr. Madhava Rao worked with Sandoz India Private Limited, Eugia Pharma Specialities Limited, Stabicon Life Sciences, Laurus Labs Limited, Abdi Ibrahim Pharmaceuticals, Aurobindo Pharma Limited and Ranbaxy Research Laboratories.</p> <p>He did Master's of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali, India, 2003 and Bachelor of Pharmacy from Osmania University, India, 2001.</p>
5	Disclosure of relationship between Directors	Not Applicable	Not Applicable

This is for your information and records.

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer